Drug Development · global
More Evidence for Once-Daily Oral Treatment: Phase 2 Trial of Emvistegrast Improves Ulcerative Colitis Remission Rates
After 12 weeks of treatment, about three in ten patients in the 200 mg group achieved clinical remission, compared with 8% in the placebo group. The findings support advancing to Phase 3 trials, but questions remain about whether efficacy can be sustained and whether the results apply to more patients whose previous treatments have failed.
For patients with ulcerative colitis who have responded inadequately to existing treatments, the significance of a new drug lies in whether it can provide more consistent disease control. Gilead announced on October 19 that its once-daily investigational oral drug emvistegrast met the primary efficacy endpoint in the Phase 2 SWIFT trial and showed a higher clinical remission rate, providing a basis for further development of this oral therapy.
According to data released by the company, 66% of patients taking 200 mg daily achieved “clinical response” after 12 weeks of treatment, compared with 37% in the placebo group. For the more stringent measure of “clinical remission,” the rates were 31% and 8%, respectively. These two measures address different levels of improvement: an improvement in disease activity cannot be equated with improvement sufficient to meet remission criteria, and remission does not mean the disease has been cured.
STAT reported the same day that the clinical remission rate at the 200 mg dose was 23 percentage points higher than with placebo, a statistically significant difference. In an interview, Swati Tole, Gilead’s head of clinical development for inflammatory disease medicines, noted that even with multiple treatments available, some patients continue to experience symptoms and do not achieve remission. This also illustrates that new therapies need to demonstrate more than convenient dosing; they must also show whether they can address gaps left by existing treatments.
Emvistegrast, formerly known as GS-1427, is an oral inhibitor targeting α4β7 integrin. SWIFT, registered as NCT06290934, is a randomized, double-blind, placebo-controlled, multicenter dose-finding trial with clinical response at Week 12 as its primary endpoint. According to the trial registry, eligible participants were adults aged 18 to 75 with moderately to severely active ulcerative colitis who had experienced an inadequate response, loss of response, or intolerance to existing treatments.
However, these participants do not represent all patients with difficult-to-treat disease. The trial excluded people who had previously received vedolizumab or other integrin antagonists, so the current findings have limited applicability to those whose disease remains uncontrolled after receiving such treatments. This eligibility criterion also makes the future positioning of emvistegrast in the treatment pathway an important question for further research.
Another limitation is time. The 12-week data show initial treatment effects but are insufficient to determine how long remission can be maintained or to fully characterize the risks of long-term use. The comparator in this trial was placebo, so even though the results are encouraging, they cannot establish that emvistegrast is superior to other approved therapies.
Gilead plans to begin Phase 3 trials of emvistegrast monotherapy in 2027. The next step is to confirm whether the efficacy observed here can be reproduced in larger studies and assessed alongside long-term safety and sustained disease control. For patients, once-daily oral dosing is a convenient way to take treatment; whether it becomes a reliable new option still depends on these clinical answers.